

Supplementary Table S9 – Correlation between risk groups and progression-free survival of doxorubicin or gemcitabine

	PFS Doxorubicin (95% CI)	p
<i>Gene Signature</i> - Low-risk group (n=49) - High-risk group (n=20)	6.1 (4.5-7.6) 3.4 (0.0-7.4)	0.247
	PFS Gemcitabine (95% CI)	p
<i>Gene Signature</i> - Low-risk group (n=55) - High-risk group (n=22)	4.1 (2.9-5.3) 3.7 (0.6-6.7)	0.113